NUDT15 and inflammatory bowel disease: Hence recommendations have been developed for adjusting the starting doses of AZA, 6MP, and 6TG based on TPMT and NUDT15 genotypes, and testing of genetic polymorphisms in IBD patients has been implemented in clinical practice [73].